- Home
- GENK vs PMN Comparison
GENK vs PMN Comparison
Compare GENK & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- PMN
- Stock Information
- Founded
- GENK 2011
- PMN 2004
- Country
- GENK United States
- PMN Canada
- Employees
- GENK N/A
- PMN N/A
- Industry
- GENK Restaurants
- PMN Pharmaceuticals and Biotechnology
- Sector
- GENK Consumer Discretionary
- PMN Health Care
- Exchange
- GENK Nasdaq
- PMN Nasdaq
- Market Cap
- GENK 36.5M
- PMN 33.7M
- IPO Year
- GENK 2023
- PMN N/A
- Fundamental
- Price
- GENK $6.87
- PMN $0.93
- Analyst Decision
- GENK Strong Buy
- PMN
- Analyst Count
- GENK 3
- PMN 0
- Target Price
- GENK $13.17
- PMN N/A
- AVG Volume (30 Days)
- GENK 54.5K
- PMN 49.2K
- Earning Date
- GENK 03-05-2025
- PMN 11-14-2024
- Dividend Yield
- GENK N/A
- PMN N/A
- EPS Growth
- GENK 483.78
- PMN N/A
- EPS
- GENK 0.17
- PMN N/A
- Revenue
- GENK $198,834,000.00
- PMN N/A
- Revenue This Year
- GENK $14.66
- PMN N/A
- Revenue Next Year
- GENK $21.47
- PMN N/A
- P/E Ratio
- GENK $41.10
- PMN N/A
- Revenue Growth
- GENK 12.50
- PMN N/A
- 52 Week Low
- GENK $5.61
- PMN $0.87
- 52 Week High
- GENK $14.46
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- GENK 34.31
- PMN 47.68
- Support Level
- GENK $7.11
- PMN $0.89
- Resistance Level
- GENK $7.54
- PMN $1.02
- Average True Range (ATR)
- GENK 0.33
- PMN 0.07
- MACD
- GENK -0.02
- PMN -0.01
- Stochastic Oscillator
- GENK 4.39
- PMN 24.04
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.